News

An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration

An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration

An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration

Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have

Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase

Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race. The stock climbed more than 2,700% in 2020.

But as the biotech company fell behind in the race, so did its shares. Novavax

Nano-X Imaging (NASDAQ: NNOX), DermTech (NASDAQ: DMTK), and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk.

Share

Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive

Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug

Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug

Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug

For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed

For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed

For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed

Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a

An up-and-coming stock with lots of potential is Viking Therapeutics (NASDAQ: VKTX). Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a

Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly.

Three Motley Fool contributors think they've identified stocks

Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly.

Three Motley Fool contributors think they've identified stocks

Axsome Therapeutics (NASDAQ: AXSM) stock jumped more than 10% on June 14 after the company made its latest investor presentation public. The market was reacting to new estimates that suggest peak

Axsome Therapeutics (NASDAQ: AXSM) started out last year as a small up-and-coming biotech company. It finished the year with a more than 100% gain, beating the bear market and crushing the S&P 500

Shares of Schrödinger (NASDAQ: SDGR) were up by 28.6% for the week on Friday morning after rising as high as 30.8%, according to data provided by S&P Global Market Intelligence. The drug discovery

Soon enough, there's a big chance that the plucky biotech Coherus Biosciences (NASDAQ: CHRS) is going to be eating AbbVie's (NYSE: ABBV) lunch. Assuming it does, it's not going to be stealing a fry